MaxCyte Past Earnings Performance

Past criteria checks 0/6

MaxCyte's earnings have been declining at an average annual rate of -27.6%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 15.7% per year.

Key information

-27.6%

Earnings growth rate

-14.8%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate15.7%
Return on equity-16.8%
Net Margin-78.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How MaxCyte makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:MYE0 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2446-365823
30 Jun 2445-355824
31 Mar 2444-375824
31 Dec 2341-385724
30 Sep 2338-375324
30 Jun 2341-335023
31 Mar 2341-304822
31 Dec 2244-244420
30 Sep 2242-244417
30 Jun 2241-204115
31 Mar 2239-163613
31 Dec 2134-193215
30 Sep 2132-172617
30 Jun 2129-172119
31 Mar 2127-161820
31 Dec 2026-121618
30 Sep 2024-111517
30 Jun 2024-91516
31 Mar 2023-111417
31 Dec 1922-131318
30 Sep 1920-131317
30 Jun 1918-141316
31 Mar 1917-111214
31 Dec 1817-91211
30 Sep 1816-101112
30 Jun 1815-101112
31 Mar 1814-101112
31 Dec 1714-101111
30 Sep 1713-8119
30 Jun 1713-6117
31 Mar 1713-5106
31 Dec 1612-495
30 Sep 1611-484
30 Jun 1611-374
31 Mar 1610-363
31 Dec 159-463
30 Sep 159-463
30 Jun 158-463
31 Mar 158-453
31 Dec 147-452
31 Dec 137-352

Quality Earnings: MYE0 is currently unprofitable.

Growing Profit Margin: MYE0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MYE0 is unprofitable, and losses have increased over the past 5 years at a rate of 27.6% per year.

Accelerating Growth: Unable to compare MYE0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYE0 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).


Return on Equity

High ROE: MYE0 has a negative Return on Equity (-16.75%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies